Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 13/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553271 | 0.90 | CYP1A2 (0.38) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14368949 | 0.90 | CYP1A2 (0.38) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5661318 | 0.90 | CYP1A2 (0.38) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14392528 | 0.90 | CYP1A2 (0.38) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4427374 | 0.90 | CYP1A2 (0.38) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4427379 | 0.90 | CYP1A2 (0.38) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4432632 | 0.90 | CYP1A2 (0.38) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4566460 | 0.90 | CYP1A2 (0.38) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4553338 | 0.90 | CYP2D6 (0.41) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14369011 | 0.90 | CYP2D6 (0.41) | CCR3CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | CCR3 247/4885CYP1A2 285/4885CYP3A4 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.